Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BDTX-4933 |
Synonyms | |
Therapy Description |
BDTX-4933 inhibits BRAF mutations, including class 1, 2 and 3 mutations, and active RAF dimers, which potentially decreases tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 3415). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BDTX-4933 | BDTX4933|BDTX 4933 | BRAF Inhibitor 25 | BDTX-4933 inhibits BRAF mutations, including class 1, 2 and 3 mutations, and active RAF dimers, which potentially decreases tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 3415). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF class 2 | Advanced Solid Tumor | predicted - sensitive | BDTX-4933 | Preclinical - Cell culture | Actionable | In a preclinical study, BDTX-4933 inhibited proliferation of cells expressing a BRAF class 2 mutation in culture (Eur J Cancer (2022), Vol 174, Supplement 1: S86). | detail... |
BRAF class 1 | Advanced Solid Tumor | predicted - sensitive | BDTX-4933 | Preclinical - Cell culture | Actionable | In a preclinical study, BDTX-4933 inhibited proliferation of cells expressing a BRAF class 1 mutation in culture (Eur J Cancer (2022), Vol 174, Supplement 1: S86). | detail... |
BRAF class 3 | Advanced Solid Tumor | predicted - sensitive | BDTX-4933 | Preclinical - Cell culture | Actionable | In a preclinical study, BDTX-4933 inhibited proliferation of cells expressing a BRAF class 3 mutation in culture (Eur J Cancer (2022), Vol 174, Supplement 1: S86). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05786924 | Phase I | BDTX-4933 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | Active, not recruiting | USA | 0 |